Anti-PCSK9 Antibody, Highly Galactosylated (BioBet-GA-407ZP) (CAT#: BioBet-GA-407ZP) Datasheet

PCSK9

Proprotein Convertase Subtilisin/Kexin Type 9

This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]

PCSK9 inhibitors; PCSK9; proprotein convertase subtilisin/kexin type 9; HCHOLA3, hypercholesterolemia, autosomal dominant 3; FH3; NARC 1; NARC1; NARC-1; HCHOLA3;

Extracellular region or secreted, Golgi apparatus, Endosome, Lysosome, Endoplasmic reticulum

Its related pathways are Neuroscience and Lipoprotein metabolism.

Play a key role in regulating plasma cholesterol homeostasis. With members of the low density lipid receptor family: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 ( The combination of LRP8/APOER2) promotes its degradation in the acidic compartment of the cell. Through a non-proteolytic mechanism, through the clathrin LDLRAP1/arh-mediated pathway, enhance the degradation of liver LDLR. It may prevent LDLR from circulating from endosomes to the cell surface or direct it to lysosome degradation. Can induce ubiquitination of LDLR, leading to its degradation. The autophagosome/lysosome pathway inhibits APOB degradation in cells in a ldlr-independent manner. Involved in processing the non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibition of epithelial Na(+) channel (ENaC)-mediated Na(+) absorption, mainly by increasing the proteasome degradation of ENaC to reduce its surface expression. Regulate neuronal apoptosis by regulating LRP8/APOER2 levels and related anti-apoptotic signaling pathways. 发送反馈 历史记录

Cell Biology and Cellular Response antibody; Developmental Biology antibody; Metabolism antibody; Signaling Transduction antibody

Cleavage by furin and PCSK5 generates a truncated inactive protein that is unable to induce LDLR degradation. Undergoes autocatalytic cleavage in the endoplasmic reticulum to release the propeptide from the N-terminus and the cleavage of the propeptide is strictly required for its maturation and activation. The cleaved propeptide however remains associated with the catalytic domain through non-covalent interactions, preventing potential substrates from accessing its active site. As a result, it is secreted from cells as a propeptide-containing, enzymatically inactive protein. Phosphorylation protects the propeptide against proteolysis.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG2, λ

Evolocumab

Human

Human

The Highly Galactosylated Anti-PCSK9 (Evolocumab), a biobetter antibody contains with a high level of galactosylation.

Atherosclerosis

Atherosclerosis